Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis

Background Blood-based biomarkers have emerged as promising tools to optimize treatment decisions in multiple sclerosis (MS) including initiation, switch, or cessation of disease modifying therapies. Objectives The clinically validated MS disease activity (MSDA) test measures 18 proteins to derive a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Angela Sanchez, Elisa Sheng, Sarah Eagleman, James L Eubanks, Patricia Izbicki, Shannon McCurdy, Matt Burrill, Ferhan Qureshi, Ati Ghoreyshi, Mitzi Joi Williams, Megan Weigel, William Kilgo, Jacqueline Nicholas, Annette Okai, Martin Belkin, Julie Burnham, Yasir Jassam, Michael Sy, Taylor Gonyou
Format:	Artigo
Idioma:	Inglês
Publicat:	SAGE Publishing 2025-04-01
Col·lecció:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Accés en línia:	https://doi.org/10.1177/20552173251331030
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!